Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (21-30 of 399) with videos related to

Pageof 40
Sort By:
Nature Reviews. Nephrology|August 25, 2011
Diabetes: bardoxolone improves kidney function in type 2 diabetesMerlin C Thomas, Mark E Cooper
Nature Reviews. Nephrology|November 26, 2009
Diabetes: RAS inhibition: probably not a one-size-fits-all approachDrazenka Pongrac Barlovic, Mark E Cooper
Amino Acids|October 22, 2010
Glycation in diabetic nephropathyJosephine M Forbes, Mark E Cooper
Diabetes|March 23, 2013
Tandem inhibition of PKC in Diαβetic nephropathy: it takes two to tango?Vicki Thallas-Bonke, Mark E Cooper
Current Pharmaceutical Design|May 14, 2008
The role of AGEs in cardiovascular diseaseKarin Jandeleit-Dahm, Mark E Cooper
Nature Reviews. Nephrology|July 29, 2024
The GLP-1 receptor agonist revolution comes to nephrologyMerlin C Thomas, Mark E Cooper
Nature Reviews. Nephrology|February 1, 2011
Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathyStephen P Gray, Mark E Cooper
Current Atherosclerosis Reports|August 13, 2003
Microalbuminuria and diabetic cardiovascular diseaseRichard J MacIsaac, Mark E Cooper
Expert Opinion on Emerging Drugs|October 28, 2023
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?Seng Kiong Tan, Mark E Cooper
Physiological Reviews|January 11, 2013
Mechanisms of diabetic complicationsJosephine M Forbes, Mark E Cooper
Pageof 40

Showing results (21-30 of 399) with videos related to

Sort By:
Pageof 40
Nature Reviews. Nephrology|August 25, 2011
Diabetes: bardoxolone improves kidney function in type 2 diabetesMerlin C Thomas, Mark E Cooper
Nature Reviews. Nephrology|November 26, 2009
Diabetes: RAS inhibition: probably not a one-size-fits-all approachDrazenka Pongrac Barlovic, Mark E Cooper
Amino Acids|October 22, 2010
Glycation in diabetic nephropathyJosephine M Forbes, Mark E Cooper
Diabetes|March 23, 2013
Tandem inhibition of PKC in Diαβetic nephropathy: it takes two to tango?Vicki Thallas-Bonke, Mark E Cooper
Current Pharmaceutical Design|May 14, 2008
The role of AGEs in cardiovascular diseaseKarin Jandeleit-Dahm, Mark E Cooper
Nature Reviews. Nephrology|July 29, 2024
The GLP-1 receptor agonist revolution comes to nephrologyMerlin C Thomas, Mark E Cooper
Nature Reviews. Nephrology|February 1, 2011
Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathyStephen P Gray, Mark E Cooper
Current Atherosclerosis Reports|August 13, 2003
Microalbuminuria and diabetic cardiovascular diseaseRichard J MacIsaac, Mark E Cooper
Expert Opinion on Emerging Drugs|October 28, 2023
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?Seng Kiong Tan, Mark E Cooper
Physiological Reviews|January 11, 2013
Mechanisms of diabetic complicationsJosephine M Forbes, Mark E Cooper
Pageof 40